Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors

References

• AledortLMComparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII bypass activityJ Thromb Haemost200421700815456478
   PubMed Web of Science ®Google Scholar
• AllenGAledortLTherapeutic decision-making in inhibitor patientsAm J Haematol200681712
   PubMed Web of Science ®Google Scholar
• AstermarkJDonfieldSMDiMicheleDMA randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) StudyBlood20071095465116990605
   PubMed Web of Science ®Google Scholar
• DargaudYLienhartAMeunierSMajor surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decisionHaemophilia200511552816128902
   PubMed Web of Science ®Google Scholar
• DelgadoJJimenez-YusteVHernandez-NavarroFAcquired haemophlia: review and meta-analysis focused on therapy and prognostic factorsBr J Haematol2003121213512670328
   PubMed Web of Science ®Google Scholar
• DimicheleDNegrierCA retrospective postlicensure survey of FEIBA efficacy and safetyHaemophilia2006123526216834734
   PubMed Web of Science ®Google Scholar
• EhrlichHHenzlMJGompertsEDSafety of factor VIII bypass activity (FEIBA):10-year compilation of thrombotic adverse eventsHaemophilia2002883911952842
   PubMed Web of Science ®Google Scholar
• FunckMSchmidtHEscuriola-EttinghausenCRadiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxisAnn Hematol19987717149829849
   PubMed Web of Science ®Google Scholar
• GreenDLechnerKA survey of 215 non-hemophilic patients with inhibitors to factor VIIIThomb Haemost1997452003
   Google Scholar
• HayCRNegrierCLudlamCAThe treatment of bleeding in acquired haemophilia with recombinant favtor VIIa: a multicenter studyThromb Haemost199778146379423795
   PubMed Web of Science ®Google Scholar
• HilgartnerMAledortLAndesAEfficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study GroupTransfusion199030626302402777
   PubMed Web of Science ®Google Scholar
• HilgartnerMWMakipernaaADimicheleDMLong-term FEIBA prophylaxis does not prevent progression of existing joint diseaseHaemophilia20039261812694515
   PubMed Web of Science ®Google Scholar
• HolmePABrosstadFTjønnfjordGEAcquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodiesHaemophilia20051151051516128896
   PubMed Web of Science ®Google Scholar
• IngerslevJPoulsenLHSørensenBPotential role of dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophiliaHaemophilia200393485212828667
   PubMed Web of Science ®Google Scholar
• KasperCKEffect of prothrombin complex concentrates on factor VIII inhibitor levelsBlood197954135868508942
   PubMed Web of Science ®Google Scholar
• KenetGLubetskyALuboshitzJA new approach to treatment of bleeding episodes in young hemophilia patients: a single megadose of recombinant activated factor VII (NovoSeven)J Thromb Haemost20031450512871449
   PubMed Web of Science ®Google Scholar
• KeyNSAledortLMBeardsleyDHome treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitorsThromb Haemost19988091289869160
   PubMed Web of Science ®Google Scholar
• KeyNSChristieBHendersonNPossible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapyThromb Haemost20028860512152680
   PubMed Web of Science ®Google Scholar
• KeyNSInhibitors in congenital coagulation disordersBr J Haematol20041273799115521914
   PubMed Web of Science ®Google Scholar
• KreuzWEscuriola-EttinghausenCFunckMWhen should prophylactic treatment in patients with haemophilia A and B start? The German experienceHaemophilia1998441379873763
   PubMed Web of Science ®Google Scholar
• KreuzWEscuriola-EttinghausenCMartinezIEfficacy and safety of factor VIII inhibitor bypass activity (FEIBA) for long-term prophylaxis in patients with high-responding inhibitorsBlood2000a96Suppl265a
   Google Scholar
• KreuzWEscuriola-EttinghausenCFactor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitorsBlood2000b96Suppl266a
   Google Scholar
• LeissingerCAUse of prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitorsHaemophilia19995Suppl 3253210597385
   PubMedGoogle Scholar
• LeissingerCWulffKAbdouAInhibitor prevalence and association with morbidity in severe hemophilia A patientsBlood200198Suppl535a
   Google Scholar
• LeissingerCAPrevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical directionAm J Hematol2004771879315389908
   PubMed Web of Science ®Google Scholar
• LottenbergRKentroTBKitchensCSAcquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapyArch Intern Med19871471077813109341
   PubMed Web of Science ®Google Scholar
• LusherJMBlattPMPennerJAAutoplex versus proplex: A controlled double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIIIBlood1983621135386414555
   PubMed Web of Science ®Google Scholar
• MakrisMvan VeenJJComparative thrombotic event incidence after infusion of recombinant FVIIa versus factor FVIII inhibitor bypass activity – a rebuttalJ Thromb Haemost20053818915842387
   PubMed Web of Science ®Google Scholar
• MathewPCurrent opinion on inhibitor treatment optionsSem Hematol200643Suppl 4813
   Google Scholar
• NegrierCGoudemandJSultanYMulticenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA study group. Factor Eight Bypassing ActivityThromb Haemost199777111399241742
   PubMed Web of Science ®Google Scholar
• NilssonIMBerntorpELöfqvistTTenty-five years’ experience of prophylactic treatment in severe hemophilia A and BJ Intern Med199223225321640190
   PubMed Web of Science ®Google Scholar
• PrestonFEDinsdaleRCWSutcliffeDJFactor VIII inhibitor by-passing activity (FEIBA) in the management of patients with factor VIII inhibitorsThromb Res19771164351929513
   PubMed Web of Science ®Google Scholar
• SallahSIsaksenMSeremetisSComparative thrombotic event incidence after infusion of recombinant FVIIa vs factor FVIII inhibitor bypass activity – a rebuttalJ Thromb Haemost20053820215842389
   PubMed Web of Science ®Google Scholar
• SaxonBRShanksDJoryCBEffective prophylaxis with daily recombinant factor FVIIa (rFVIIa-Novoseven) in a child with high-titre inhibitors and a target jointThromb Haemost2001861126711686341
   PubMed Web of Science ®Google Scholar
• ScharrerIBrayGNetzlingOIncidence of inhibitors in hemophilia A patients: a review of recent studies of recombinant and plasma-derived factor VIII concentratesHaemophilia199951455410444280
   PubMed Web of Science ®Google Scholar
• SchneidermanJNugentDJYoungGSequential therapy with activated prothrombin complex concentrate and recombinant factor FVIIa in patients with severe haemophilia and inhibitorsHaemophilia2004103475115230948
   PubMed Web of Science ®Google Scholar
• SeremetisSDose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitorsBlood Coagul Fibrinolysis200314Suppl 12930
   Google Scholar
• ShapiroSSHultinMAcquired inhibitors to the blood coagulation factorsSemin Thromb Haemost1975133685
   Google Scholar
• SjamsoedinLJHeijnenLMauser-BunshotenEPThe effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A nd antibodies to factor VIII. A double-blind clinical trialN Eng J Med198130571721
   PubMed Web of Science ®Google Scholar
• SørensenBIngerslevJWhole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIaJ Thromb Haemost200421021014717973
   PubMed Web of Science ®Google Scholar
• TriemstraMRosendaalFRSmitCMortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986Ann Intern Med199512382377486463
   PubMed Web of Science ®Google Scholar
• TurecekPLVáradiKGritschHFactor Xa and prothrombin. Mechanism of action of FEIBAVox Sang199977Suppl 172910529694
   PubMedGoogle Scholar
• TurecekPLVáradiKKeilBFactor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assayPahtophysiol Haemost Thromb2003331622
   PubMedGoogle Scholar
• UK Haemophilia Center Doctors’ Organization (UKHCDO)The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–1999J Thromb Haemost2004210475415219185
   PubMed Web of Science ®Google Scholar
• ValentinoLASalitMGProphlactic use of FEIBA in children with hemophilia complicated by high-titered inhibitorsBlood2002100Suppl102b
   Google Scholar
• WarrierIData presented at the meeting of the Factor VIII and Factor IX Scientific Subcommittee of the SSC at the ISTH200349th Annual Scientific and Standardization Committee meetingBirmingham, UK http://www.med.unc.edu/isth/
   Google Scholar
• WightJPaislySThe epidemiology of inhibitors in hemophilia A: a systematic reviewHaemophilia200394183512828678
   PubMed Web of Science ®Google Scholar
• YoungGMcDanielMNugentDJProphylactic recombinant factor VIIa in haemophilia patients with inhibitorsHaemophilia20051120320715876264
   PubMed Web of Science ®Google Scholar